The DTWD1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cervical adenocarcinoma cell line. This polyclonal pool contains a heterogeneous mix of DTWD1-disrupted alleles, offering a robust model for functional studies without clonal selection artifacts. The format enables assessment of gene loss effects across diverse genetic backgrounds, minimizing biases from single-cell cloning. It is a versatile tool for dissecting DTWD1??s role in cancer biology and for high-throughput screening applications.
HeLa cells are an immortalized epithelial line originating from a cervical adenocarcinoma, positive for human papillomavirus type 18 (HPV-18) and characterized by inactivation of p53 and RB tumor suppressors. This background results in uncontrolled proliferation and resistance to apoptosis, making HeLa cells a standard model for cancer biology, virology, and oncogenic signaling research. Their ease of culture and genetic manipulation further support knockout studies of proliferation- and survival-related genes.
DTWD1 encodes a DTW domain-containing protein predicted to participate in tRNA wybutosine modification, a process critical for translational fidelity. The protein is hypothesized to modulate PI3K/Akt/mTOR signaling, a central pathway in cell growth and survival. Upstream regulators include growth factors EGF and IGF, acting through receptor tyrosine kinases and PI3K. DTWD1 interacts with PIK3R1, the PI3K regulatory subunit, and influences downstream targets such as Akt, mTOR, S6K, and 4E-BP1, which in turn regulate cyclins and Bcl-2 family proteins to control cell cycle progression and apoptosis.
Within the HeLa context, HPV-18 oncoproteins E6 and E7 drive constitutive proliferation, and DTWD1 knockout can reveal vulnerabilities in the PI3K/Akt/mTOR axis that are otherwise compensated. Loss of DTWD1 is predicted to reduce Akt phosphorylation, dampen mTOR-driven protein synthesis, and promote apoptosis, thereby exposing synthetic lethal interactions. This model is particularly valuable for studying chemoresistance mechanisms in cervical adenocarcinoma and for validating therapeutic targets in the PI3K pathway.
This polyclonal knockout model supports diverse applications, including functional genomics, investigation of tRNA modification in cancer, and drug target validation for the PI3K/Akt/mTOR pathway. Phenotypic characterization can be performed using Western blotting for phospho-Akt (Ser473), phospho-mTOR, and cyclin D1, alongside MTS/BrdU proliferation assays and Annexin V apoptosis staining. Cell cycle analysis by flow cytometry, colony formation, and migration/invasion assays provide additional functional readouts, while RNA-seq enables transcriptome-wide profiling. For further information, please contact Ascent Research.
